CytomX Therapeutics, Inc.
CTMXNASDAQHealthcare● Active
$2.90
$-0.10(-3.33%)
Market Cap$466388234
P/E Ratio—
52W High$8.21
52W Low$1.72
CytomX Therapeutics, Inc. (CTMX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CTMX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.10
Est. -$0.14 · +28.6%
Revenue
$0.01B
Est. $0.00B · +119.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
CTMX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.36
Rev. $5.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.36
Rev. Est.$5.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.11 | — | — | — | $0.01B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.14 | -$0.10 | +28.6% | $0.01B | $0.00B | +119.1% |
| ▼ Q1 FY2026 | Mar 16, 2026 | -$0.08 | -$0.22 | -175.0% | $0.00B | $0.01B | -91.0% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.05 | -$0.09 | -82.5% | $0.01B | $0.01B | -18.6% |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.06 | -$0.00 | +98.1% | $0.02B | $0.02B | +2.1% |
| ▲ Q2 FY2025 | May 12, 2025 | $0.12 | $0.27 | +116.3% | $0.05B | $0.04B | +43.7% |
| ▲ Q1 FY2025 | Mar 6, 2025 | -$0.23 | $0.22 | +195.7% | $0.04B | $0.01B | +192.1% |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.17 | $0.07 | +141.2% | $0.03B | $0.01B | +147.0% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.11
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.10
EPS Est.
-$0.14
EPS Surpr.
+28.6%
Revenue
$0.01B
Q1 FY2026
Mar 16, 2026Miss
EPS Actual
-$0.22
EPS Est.
-$0.08
EPS Surpr.
-175.0%
Revenue
$0.00B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.09
EPS Est.
-$0.05
EPS Surpr.
-82.5%
Revenue
$0.01B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$0.00
EPS Est.
-$0.06
EPS Surpr.
+98.1%
Revenue
$0.02B
Q2 FY2025
May 12, 2025Beat
EPS Actual
$0.27
EPS Est.
$0.12
EPS Surpr.
+116.3%
Revenue
$0.05B
Q1 FY2025
Mar 6, 2025Beat
EPS Actual
$0.22
EPS Est.
-$0.23
EPS Surpr.
+195.7%
Revenue
$0.04B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
$0.07
EPS Est.
-$0.17
EPS Surpr.
+141.2%
Revenue
$0.03B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.40 | $-0.16 | $-0.02 | 1 |
| Q3 FY2027 | $-0.38 | $-0.15 | $-0.02 | 1 |
| Q2 FY2027 | $-0.37 | $-0.15 | $-0.02 | 1 |
| Q1 FY2027 | $-0.34 | $-0.14 | $-0.02 | 1 |
| Q4 FY2026 | $-0.29 | $-0.12 | $-0.02 | 1 |
| Q3 FY2026 | $-0.13 | $-0.11 | $-0.09 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +28.6% | $4.13 | $4.00 | -3.15% |
| ▼ Q1 FY2026 | Mar 16, 2026 | -175.0% | $4.68 | $6.75 | +44.23% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -82.5% | $4.21 | $4.19 | -0.48% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +98.1% | $2.17 | $2.10 | -3.23% |
| ▲ Q2 FY2025 | May 12, 2025 | +116.3% | $0.93 | $2.13 | +129.43% |
| ▲ Q1 FY2025 | Mar 6, 2025 | +195.7% | $0.62 | $0.62 | +0.34% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +141.2% | $1.00 | $1.00 | +0.00% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +42.9% | $1.16 | $1.18 | +1.72% |
Q2 FY2026-3.15%
Report Date
May 7, 2026
EPS Beat/Miss
+28.6%
Price Before
$4.13
Price After
$4.00
Q1 FY2026+44.23%
Report Date
Mar 16, 2026
EPS Beat/Miss
-175.0%
Price Before
$4.68
Price After
$6.75
Q4 FY2025-0.48%
Report Date
Nov 6, 2025
EPS Beat/Miss
-82.5%
Price Before
$4.21
Price After
$4.19
Q3 FY2025-3.23%
Report Date
Aug 7, 2025
EPS Beat/Miss
+98.1%
Price Before
$2.17
Price After
$2.10
Q2 FY2025+129.43%
Report Date
May 12, 2025
EPS Beat/Miss
+116.3%
Price Before
$0.93
Price After
$2.13
Q1 FY2025+0.34%
Report Date
Mar 6, 2025
EPS Beat/Miss
+195.7%
Price Before
$0.62
Price After
$0.62
Q4 FY2024+0.00%
Report Date
Nov 7, 2024
EPS Beat/Miss
+141.2%
Price Before
$1.00
Price After
$1.00
Q3 FY2024+1.72%
Report Date
Aug 8, 2024
EPS Beat/Miss
+42.9%
Price Before
$1.16
Price After
$1.18
Avg Beat Reaction+20.85%
Avg Miss Reaction+21.88%
Beat Rate6 / 8 quarters
Largest Move+129.43% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CTMX ends December
CytomX Therapeutics, Inc. (CTMX) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.10 — beating the analyst consensus of $-0.14 by +28.6%. The next CTMX earnings date is expected around September 1, 2026.
Each quarter, investors track CTMX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CTMX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CTMX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CTMX earnings · 5 questionsCytomX Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. CTMX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CTMX historically reports after market close (AMC).
CTMX earnings datewhen is CTMX earningsCTMX next earnings datewhen does CTMX report earningsCTMX earnings calendar
▸ Source: FMP · CytomX Therapeutics, Inc. SEC filings · US GAAP · CytomX Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026